Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation Study of ARQ 197 in Combination With Gemcitabine in Adult Patients With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent granted prior to initiation of any study-specific screening procedures, given with the understanding that the patient has the right to withdraw from the study at any time, without prejudice~* 18 year of age or older~* Histologically or cytologically confirmed locally advanced, inoperable or metastatic primary solid tumors~* Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤1~* Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x upper limit of normal (ULN) or ≤ 5 x ULN with metastatic liver disease~* Hemoglobin ≥ 10 g/dl (or ≥ 9 g/dl for expanded cohort)~* Total bilirubin ≤ 1.5 x ULN~* Serum creatinine ≤ 1.5 x ULN~* Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L~* Platelets ≥ 100 x 10\^9/L~* Women of childbearing potential must have a negative pregnancy test performed within seven days prior to the start of study drug~* Male and female subjects of child-bearing potential must agree to use double-barrier contraceptive measures, oral contraception, or avoidance of intercourse during the study and for 90 days after last investigational drug dose received~Exclusion Criteria:~* Other cancer within the last three years, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin~* Previous anti-cancer chemotherapy, radiotherapy, major surgery, immunotherapy or investigational agents within 4 weeks prior to the first day of study defined treatment~* History of cardiac disease: congestive heart failure defined as Class II to IV per New York Heart Association (NYHA) classification; active coronary artery disease (CAD); previously diagnosed bradycardia or other cardiac arrhythmia defined as ≥ Grade 2 according to National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) (version 3.0), or uncontrolled hypertension; myocardial infarction occurred within 6 months prior to study entry (myocardial infarction occurred \> 6 months prior to study entry is permitted)~* Active clinically serious infections defined as ≥ Grade 2 according to NCI CTCAE, version 3.0~* Substance abuse, medical, psychological or social conditions that may, in the opinion of the Investigator, interfere with the patient's participation in the study or evaluation of the study results~* Any condition that is unstable or which could jeopardize the safety of the patient and his/her protocol compliance~* Known human immunodeficiency virus (HIV) infection~* Pregnancy or breast-feeding~* Inability to swallow oral medications~* Significant gastrointestinal disorder, in the opinion of the Investigator, could interfere with the absorption of ARQ 197 and/or gemcitabine (e.g. significant, uncontrolled inflammatory bowel disease or extensive small bowel resection)~* Central nervous system metastases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ARQ 197 in combination with gemcitabine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).